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Abstract: A microbial imbalance called dysbiosis leads to inflammatory bowel disease (IBD), which can
include ulcerative colitis (UC). Fecal microbiota transplantation (FMT), a novel therapy, has recently
been successful in treating gut dysbiosis in UC patients. For the FMT technique to be successful,
the gut microbiota of both the healthy donors and UC patients must be characterized. For decades,
next-generation sequencing (NGS) has been used to analyze gut microbiota. Despite the popularity of
NGS, the cost and time constraints make it difficult to use in emergency services and activities related
to the periodic monitoring of microbiota profile alterations. Hence, in this study, we developed a
multiplex TaqMan qPCR assay (MTq-PCR) with novel probes to simultaneously determine the relative
proportions of the three dominant microbial phyla in the human gut: Bacteroidetes, Firmicutes,
and Proteobacteria. The relative proportions of the three phyla in fecal samples of either healthy
volunteers or UC patients were similar when assessed NGS and the MTq-PCR. Thus, our MTq-PCR
assay could be a practical microbiota profiling alternative for diagnosing and monitoring gut dysbiosis
in UC patients during emergency situations, and it could have a role in screening stool from potential
FMT donors.
Keywords: gut microbiota; next generation sequencing; primer design; qPCR; TaqMan probes;
ulcerative colitis
1. Introduction
There are more than trillions of microorganisms inhabiting the human gut, and they live in
homeostatic balance [1,2]. However, a microbial imbalance called dysbiosis causes metabolic disorders
and affects the interactions of microorganisms in the host, which can eventually lead to inflammatory
bowel disease (IBD) and ulcerative colitis (UC) [1,3]. The increasing global incidence of UC is growing,
as is the concern for treating the disease [4,5].
A novel therapy named fecal microbiota transplantation (FMT) has recently shown promise
in treating gut dysbiosis in UC patients [6–8]. However, it is difficult to determine the safety and
efficacy of FMT in UC patients, and it is also difficult to determine the factors that affect the success of
FMT [9,10]. The success of FMT may be associated with microbial shift [11,12]. Previous studies have
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characterized gut dysbiosis as an alteration in the relative abundance of the two dominant phyla in
the human gut, Bacteroidetes and Firmicutes [13]. Thus, for the FMT technique to be successful, it is
crucial to characterize and monitor the gut microbiota of UC patients [6,9].
For decades, next-generation sequencing (NGS) has been used to analyze changes in gut microbiota
composition, and it has played a critical role in advancing gut microbiome research [14–16]. Despite
the popularity of NGS, the cost and time constraints make it difficult to use for emergency services.
A rapid, sensitive, and cost-effective method is required. Conventional and quantitative PCR methods
have been useful to specifically detect organisms at the phylum level [17]. However, these methods are
not able to simultaneously quantify different phyla in a single tube. TaqMan PCR is a powerful tool for
the simultaneous detection and quantification of microbes in samples from different sources [18–20].
The relative composition of the three major phyla in the human gut, Bacteroidetes, Firmicutes, and
Proteobacteria, has been proposed as a potential diagnostic tool for UC [9,21]. This study aimed to
develop an MTq-PCR assay using novel TaqMan probes for profiling the dominant gut microbiota
phyla. Our study confirmed that MTq-PCR is a viable alternative to NGS when characterizing the
three dominant phyla (Bacteroidetes, Firmicutes, and Proteobacteria) in fecal samples from healthy
and UC patients.
2. Results
2.1. Specificity of TaqMan Probes and Primers
In this study, phylum-specific probes (Table 1) were developed, and their phylum specificity was
evaluated in silico using the SILVA database (Quast et al., 2013). The Bacteroidetes TaqMan probe (Bat1)
matched 93% of the 16S rRNA genes that were classified under Bacteroidetes in the SILVA database
when two mismatches per probe were allowed (Table 2). The Bat1 probe had low sensitivity (3.7%)
to non-target 16S rRNA gene sequences classified under Firmicutes (Table 2). Interestingly, the Bat1
probe had no predicted specificity to Enterobacteriaceae, which are the gut-dominant Proteobacteria.
The previous CFB555f and 798cfbF probes covered a large percentage (96.7 and 98.2%, respectively) of
Bacteroidetes target sequences; however, both showed very weak mismatching capabilities against
non-targets such as Firmicutes and Proteobacteria (Tables 3 and 6).
The Firmicutes probe (Fir7) covered 55.7% of its intended phyla but had very low coverage (less
than 4%) for the non-targeted phyla (Table 2). Previously reported Firmicutes-specific probes had
high (>96%) coverage for Firmicutes target sequences; however, they showed very weak mismatching
capabilities against non-target gene sequences from Bacteroidetes and Proteobacteria (Table 4 and
Table 6). Interestingly, the Proteobacteria probe (Pro3) was not predicted to bind to non-targeted phyla.
Pro3 was highly specific (94%) to Enterobacteriaceae (Table 2). Although the Pro3 probe had lower
Proteobacteria coverage than the previous Proteobacteria-specific probe, our probe had comparable
efficacy in terms of gut-dominant Proteobacteria (Enterobacteriaceae). More importantly, our probe
showed strong mismatching capabilities against non-targeted genes from Firmicutes and Bacteroidetes
(Tables 5 and 6). Overall, our probes had very low coverage (less than 4%) to non-targeted taxa (Table 2).
The three probes were designed to bind within the 16S rRNA region of the forward (Eub268) and
reverse (Eub797) primers without overlapping (Figure 6).
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Table 1. Probe and primer design.
Oligonucleotide Primer/Probe Name Target Phylum Fluoro-phore a Quencher Sequence (5’–3’) References
Probe Bat1 Bacteroidetes 6-FAM BHQ-1 GAGGCAGCAGTGAGGAATATTGGT This study
Fir7 Firmicutes HEX BHQ-1 AAGGCGACGATCGGTAGCCGRM * This study
Pro3 Proteobacteria Cy5 BHQ-2 GCCTTCGGGTTGTAAAGTACTTTCAGC This study
Eub518 Eubacteria TEX615 BHQ-2 ATTACCGCGGCTGCTGG [22]
Forward primer Eub268 Eubacteria TWGGYGRGGTAACGGCYCACCWA This study
Reverse primer Eub797 Eubacteria GGACTACCAGGGTATCTAATCCTGTT [23]
a Fluorophores were coupled to the most effective probe candidates. * RM is an ambiguous nucleotide code where R stands for A or G, and M stands for A or C.
Table 2. In silico PCR assay with newly designed probes.
Probe Target Taxon Percent Coverage in the Target Taxon (%) a
Perfect Match 1 Mismatch 2 Mismatches
Bat1 Bacteroidetes 63.7 85.2 93.0
Firmicutes 0.0 0.1 3.7
Proteobacteria 0.0 0.2 39.4
Enterobacteriaceae 0.0 0.0 0.0
Fir7 Firmicutes 2.1 13.5 55.7
Bacteroidetes 0.0 0.0 0.6
Proteobacteria 0.0 0.1 3.9
Enterobacteriaceae 0.0 0.0 0.1
Pro3 Proteobacteria 7.1 13.6 21.7
Enterobacteriaceae 75.0 92.1 94.0
Bacteroidetes 0.0 0.0 0.0
Firmicutes 0.0 0.0 0.0
a Percent sequence coverage in the target group based on the online “TestProbe” tool in the SILVA 138 SSU Ref NR database, released in January 2020.
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Table 3. Comparison of our probe with previously reported Bacteroidetes-specific probes.
Probe Sequence (5’–3’) Location * Gut Bacteroidetes (%) a All Bacteroidetes (%) a All Other Bacteria (%) a Reference
Bacteroides spp. Provotella spp.
Bat1 GAGGCAGCAGTGAGGAATATTGGT 346–369 98.5 97.9 86.2 28.0 This study
S-P-Bdet-0107-a-S-21 GCACGGGTGMGTAACRCGTAT 107–127 91.9 95.9 78.7 23.7 [24]
CFB555f CCGGAWTYATTGGGTTTAAAGGG 555–577 96.4 97.8 96.7 25.3 [25]
798cfbF CRAACAGGATTAGATACCCT 779–798 97.8 98.5 98.2 25.3 [26]
* Escherichia coli position. a Percent sequence coverage in the target group based on the online “TestProbe” tool in the SILVA 138 SSU Ref NR database, released in January 2020.
Table 4. Comparison of probes from the current study with previously reported Firmicutes-specific probes.
Probe Sequence (5’–3’) Location * Gut Firmicutes (%) a All Firmicutes (%) a All Other Bacteria (%) a Reference
Clostridiaceae Eubacteriaceae
Fir7 AAGGCGACGATCGGTAGCCGRM 272–290 75.6 8.5 55.7 24.1 This study
S-P-Firm-0352-a-S-18 CAGCAGTAGGGAATCTTC 352–369 1.4 0.6 46.9 24.2 [24]
S-P-Firm-0525-a-A-18 ACCTACGTATTACCGCGG 525–542 98.2 95.5 96.6 80.1 [24]
Firm350f GGCAGCAGTRGGGAATCTTC 350–369 95.7 96.0 87.3 72.2 [25]
928F-Firm TGAAACTYAAAGGAATTGACG 905–925 94.2 93.8 96.2 96.4 [26]
* Escherichia coli position. a Percent sequence coverage in the target group based on the online “TestProbe” tool in the SILVA 138 SSU Ref NR database, released in January 2020.
Table 5. Comparison of probes from the current study with previously reported Proteobacteria-specific probes.
Probe Sequence (5’–3’) Location * Gut Proteobacteria (Enterobacteriaceae) (%) a All Proteobacteria (%) a All other Bacteria (%) a Reference
Pro3 GCCTTCATACCACGGAGTACTTTCAGC 415–441 94.0 21.7 6.3 This study
Gamma395f CMATGCCGCGTGTGTGAA 395–412 96.3 85.6 31.7 [25]
Gamma877F GCTAACGCATTAAGTRYCCCG 859–880 0.3 9.3 31.8 [27]
* Escherichia coli position. a Percent sequence coverage in the target group based on the online “TestProbe” tool in the SILVA 138 SSU Ref NR database, released in January 2020.
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Table 6. Comparison of the specificity between probes from the current study with those previously reported.
Target Phylum Probe/Primer Target Taxon Percent Coverage in the Target Taxonomy (%)
















































* Probes designed in this study are indicated in bold.
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2.2. In Vitro Evaluation of the Multiplex Taqman Assay
The specificity of the probes used to detect three bacteria strains (Bacteroides fragilis GUT-04,
Clostridium butyricum TO-A, and Shigella sonnei KCCM 41282) within different phyla was evaluated in
a singleplex and multiplex conventional PCR reaction. In the singleplex PCR assay, primer pairs for
Eubacteria, Eub268, and Eub797 successfully amplified a single band of 529 bp from each of the three
bacterial strains (Figure 1A–C). However, the probe designed for Bacteroidetes, Bat1, only amplified the
target strain, B. fragilis, and no PCR product was detected for non-target strains. Similarly, the Fir7 and
Pro3 primers only amplified their intended target strain (Figure 1B and C), suggesting that the probes
were specific. In the multiplex PCR, wherein a mock community of three strains was constructed, the
probes specifically amplified their target strains, and the probes were sensitive enough to discriminate
all strains mixed in a single tube (Figure 2). These results indicated that the designed primer and probe
sets did not interfere with each other in the multiplex PCR reaction. In contrast, primers designed to
detect Eubacteria failed to discriminate between the strains used in the PCR reaction (Figure 2).
Figure 1. Agarose gel electrophoresis of singleplex PCR products produced by phylum-specific probes
for (A) Bacteroides fragilis GUT-04, (B) Clostridium butyricum TO-A, and (C) Shigella sonnei KCCM 41282.
M: marker 1kb DNA ladder; Lane 1: 27F/1492R; Lane 2: negative control; Lane 3: Bat1/1492R; Lane
4: Fir7/1492R; Lane 5: Pro3/1492R; and Lane 6: Eub268/Eub797. The universal primer set, 27F/1492R,
without template DNA, served as the negative control.
Figure 2. Agarose gel electrophoresis of multiplex PCR products. Letters B, F, and P signify the DNA
template extracted from B. fragilis GUT-04, C. butyricum TO-A, and S. sonnei KCCM 41282, respectively.
B+F, B+P, F+P, and B+F+P represent mock communities. M: marker 1kb DNA ladder; Lane 1: positive
control; Lane 2: negative control; Lane 3: Bat1+Eub797; Lane 4: Fir7+Eub797; Lane 5: Pro3+Eub797;
Lane 6: Bat1+Fir7+Eub797; Lane 7: Bat1+Pro3+Eub797; Lane 8: Fir7+ Pro3+Eub797; and Lane 9:
Bat1+Fir7+Pro3+Eub797. A eubacterial primer set, Eub268/Eub797, with template DNA from the
mock community without probes served as the positive control, and a primer set, 27F/1492R, without
template DNA, served as the negative control.
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2.3. Comparison of Multiplex TaqMan qPCR (MTq-PCR) and NGS
The sensitivity of the MTq-PCR and NGS methods in determining the relative proportions of
the three phyla from fecal samples collected from healthy and UC patients were compared. The
relative proportions of the three phyla in fecal samples of either healthy volunteers or UC patients
were similar for both methods. In fecal samples from healthy individuals, the relative proportions of
Bacteroidetes and Firmicutes were much higher than the proportion of Proteobacteria. In contrast, in
UC patients, both methods showed that the percentage of Bacteroidetes was very low. In both methods,
the Firmicutes/Bacteroidetes ratio was close to 0.5 in fecal samples of healthy individuals, but the
ratio was very high in UC patients. More importantly, both methods revealed that the proportion of
Proteobacteria was high in UC fecal samples when compared to healthy individuals (Figures 3 and 4).
Figure 3. Relative proportions of the three phyla from fecal samples of healthy subjects determined by
(A) NGS and (B) MTq-PCR.
Figure 4. Relative proportions of the three phyla from fecal samples of UC patients determined by (A)
NGS and (B) MTq-PCR.
Principal coordinate analysis (PCoA) was performed to compare the profiling efficiency of NGS
and MTq-PCR (Figure 5). The relative proportions of the three dominant phyla in UC patients and
healthy volunteers were used for the analysis. The clustering of UC patients and healthy volunteers
using NGS was similar to the clustering seen when using MTq-PCR, which indicated the potential of
MTq-PCR for monitoring microbiota profile alterations.
Furthermore, the statistical analysis examining the similarity between NGS and MTq-PCR was
analyzed using multivariate similarity Anosim and Adonis tests with the Bray–Curtis distance. Based
on the Anosim and Adonis analysis, NGS and MTq-PCR were not significantly different (p > 0.05)
in profiling the abundance of the three phyla from fecal samples of either healthy volunteers or UC
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patients (Table 7). Both NGS and MTq-PCR were able to significantly discriminate (p < 0.001) the
phylum composition between healthy volunteers and UC patients (Table 8).
Figure 5. Principal coordinate analysis of (PCoA) of the three dominant phyla in the fecal samples of
UC patients and healthy volunteers using NGS and MTq–PCR.
Table 7. Adonis and Anosim statistical analyses between NGS and MTq-PCR using fecal samples
collected from healthy subjects and UC patients.
Sample Source Comparison Adonis a Anosim a
R2 p Value R p Value
Healthy NGS vs. MTq-PCR 0.002 0.868 −0.049 0.779
UC NGS vs. MTq-PCR 0.017 0.73 0.019 0.328
Across all samples NGS vs. MTq-PCR 0.001 0.961 −0.04 0.89
a Adonis and Anosim statistical analyses were carried out based on Bray–Curtis dissimilarities at the phylum level.
Table 8. Adonis and Anosim statistical analyses between NGS and MTq-PCR.
Method Comparison Adonis a Anosim a
R2 p Value R p Value
MTq-PCR Healthy vs. UC 0.745 <0.001 0.933 0.001
NGS Healthy vs. UC 0.804 <0.001 0.984 0.001
a Adonis and Anosim statistical analyses were carried out based on Bray–Curtis dissimilarities at the phylum level.
3. Discussion
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that adversely affects the
quality of a patient’s life [27,28]. Recent reports have indicated that UC is characterized by a low
diversity of intestinal bacterial flora [29,30]. The relative composition of the three major gut flora
phyla (Bacteroidetes, Firmicutes, and Proteobacteria) could be a potential diagnostic tool for UC [9,21].
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Fecal microbiota transplantation (FMT) is a novel therapy for UC that restores the composition and
function of the bacterial flora in the gut [31,32]. For FMT to be successful, it is crucial to characterize the
presence and absence of individual taxa in the samples of potential fecal donors and UC patients [33].
For decades, next-generation sequencing (NGS) has been used to analyze gut microbiota [34]. Despite
the popularity of NGS, the cost and time constraints make it difficult for emergency services to employ
it [33–35]. In addition, and of concern because the number of UC patients is rapidly increasing [36],
it is more costly to monitor the clinical efficacy of FMT (i.e., analyzing the gut microbiota) of numerous
people with NGS. A rapid, sensitive, and cost-effective method is required [20].
TaqMan qPCR is a powerful tool used in the microbial diagnosis of samples from different
sources [19]. Hence, in this study, we developed a multiplex TaqMan qPCR (MTq-PCR) with three
novel phylum-specific TaqMan probes to determine the proportions of the three dominant phyla in the
gut microbiota of UC patients (n = 6) and healthy subjects (n = 6), namely Bacteroidetes, Firmicutes,
and Proteobacteria. The effectiveness of our MTq-PCR assay in profiling the three phyla was compared
with NGS.
The phylum-specific probes and primers were designed to target 16S rRNA and were evaluated
in silico using the SILVA database [37]. Our probes were comparatively more sensitive than the
previously reported probes in discriminating non-target phyla, and they were more specific to gut
microbiota [24–26]. This indicates that our probes detected more gut microbiota than the previously
reported probes. Our probes exhibited low cross-hybridization to non-target phyla. In addition,
phylum-specific primers from previous reports were designed for a singleplex PCR and were less
sensitive at discriminating non-target taxa [17,24]. In our conventional PCR assay, none of the designed
primers and probes interfered with each other during the multiplex PCR reaction, and the reaction
was confirmed to be reproducible and sensitive. The multiplex assay showed that the probes were
specific, and it was possible to discriminate the three phyla in a single tube. Similar studies reported
that real-time PCR assays based on TaqMan hydrolysis probes were specific, sensitive, and rapid
compared to conventional PCR [20,37,38]. It is important to note that our qPCR assay was based on the
proportion of amplicons; therefore, it cannot directly measure the number of individual cells. This is
due to the fact that multiple 16S rRNA copies are found in different bacteria [39]. In connection with
multiple copies of 16S rRNA, previous studies similarly reported a biased determination of microbial
composition using an NGS approach [40]. To the best of our knowledge, this is the first study to
profile human gut microbiota with three different phylum-specific TaqMan probes in a single assay
without cross-reactivity.
In our study, both NGS and multiplex PCR methods showed a similar relative abundance between
the three major phyla in fecal samples of either UC patients or healthy subjects. Both profiling
methods also confirmed that the proportion of Bacteroidetes was greatly reduced in all fecal samples
of UC patients when compared to healthy subjects. On the other hand, both methods proved that
the relative abundance of Proteobacteria was very high in UC patients when compared to healthy
subjects. The results of our study were consistent with a previous report showing that Proteobacteria
are integral in the formation of UC, and the load of this phylum in the gut could be an effective
diagnostic criterion for UC [21]. Bacteroidetes and Firmicutes are the two dominant phyla in healthy
gut microbiota, representing about 90% of the bacterial population [13,40,41]. However, dysbiosis
(a microbial imbalance) leads to ulcerative colitis (UC) [3,9]. In our study, both NGS and MTq-PCR
showed similar results in determining dysbiosis. PCA and an Anosim and Adonis analysis revealed
that NGS and MTq-PCR were not significantly different (p > 0.05) in profiling the abundance of the
three phyla from fecal samples of either healthy volunteers or UC patients. Both NGS and MTq-PCR
indicated significant differences (p < 0.001) in the phylum composition between healthy and UC
patients. This indicates that our MTq-PCR assay could be used as an alternative method in profiling
the three dominant phyla of the gut microbiota since the assay is less costly, rapid, and more accessible
than NGS. NGS techniques are costly, time-consuming, and complex for routine applications in
resource-limited health care organizations with limited genomic facilities and trained personnel [42].
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In summary, we developed a rapid, sensitive, and cost-effective MTq-PCR assay that reliably
profiled the three major phyla in fecal samples of healthy subjects and UC patients: Bacteroidetes,
Firmicutes, and Proteobacteria. The results revealed that the proportion of the three phyla in either
healthy subjects or UC patients were similar among NGS and MTq-PCR. This suggests that our assay
could be a practical microbiota profiling alternative that can characterize the three phyla involved with
gut dysbiosis in UC patients during emergency cases of pre-FMT, and it could also help monitor the
clinical efficacy and safety of FMT in UC patients at a low cost.
4. Materials and Methods
4.1. Bacterial Strains
Three bacterial strains (B. fragilis GUT-04, C. butyricum TO-A, and S. sonnei KCCM41282)
representing the three dominant gut flora phyla (Bacteroidetes, Firmicutes, and Proteobacteria,
respectively) were obtained from Kyungpook National University culture collections. The strains
were grown in fastidious anaerobe broth medium (FAB: peptone, 23 g; soluble starch, 1 g; sodium
bicarbonate, 0.4 g; sodium chloride, 5 g; glucose, 1 g; sodium pyruvate, 1 g; L-arginine, 1 g; L-cysteine
HCL 0.5 g; sodium pyrophosphate, 0.25 g; sodium succinate, 0.5 g; Hemin, 0.01 g; and Vitamin K,
0.001 g; Seoul, South Korea) at 37 ◦C for 48 h.
4.2. Fecal Sample Collection
Fresh fecal samples from healthy volunteers (n = 10) were collected at Kyungpook National
University (KNU), Daegu, South Korea. In addition, fecal samples from six UC patients (n = 6) who
had been diagnosed with dysbiosis at Yonsei University, Seoul, South Korea were collected. Collection
of human fecal samples was performed with the approval of the Institutional Review Board (IRB)
at Yonsei University and Kyungpook National University (permit numbers: YSU4-2018-0438 and
KNU-2019-0129, respectively). All fecal samples were collected in Transwab® (Medical Wire, UK)
following the manufacturer’s protocol. Within 24 h, all collected samples were transported to our
laboratory in ice packs and stored at −70 ◦C until processing.
4.3. DNA Extraction
Genomic DNA from pure cultures of the three bacterial strains was extracted using the Wizard®
Genomic Purification Kit (Promega Corporation, USA). DNA from fecal samples was extracted using
the QIAamp Powerfecal DNA kit (QIAGEN, Germany) according to the manufacturer’s protocol. The
DNA concentration was measured using a Qubit® Fluorometer (Thermo Fisher Scientific, Waltham,
MA, USA) and stored at −20 ◦C until used.
4.4. NGS Method
The V4–V5 variable region of the 16S rRNA gene was PCR amplified using a
universal primer pair: forward (515F 5′-GTGCCAGCMGCCGCGG-3′) and reverse (907R
5′-CCGTCAATTCMTTTRAGTTT-3′). For sequencing, an Ion Torrent PGM adapter and barcode
tailored to the primer pair was used. The library preparation reactions consisted of 50 µL and were
composed of 25 µL of EmeraldAmp® Max PCR Master Mix (Takara Korea Biomedical Inc., Seoul,
Korea), 1 µL of each bacterial primer, 1 µL of extracted DNA, and 22 µL of ultra-pure water. The first
amplification reaction was performed using the following thermocycling program: pre-denaturation at
95 ◦C for 3 min, followed by five cycles of 95 ◦C for 30 s, 57 ◦C for 30 s, and 72 ◦C for 30 s. The second
amplification reaction was 30 cycles of denaturation at 95 ◦C for 30 s and annealing–extension at 72 ◦C
for 1 min. The final extension was performed at 72 ◦C for 5 min [43].
In this study, NGS was employed, and the quality of the amplified DNA library was assessed
using an Agilent 2100 Bioanalyzer High-Sensitivity DNA Assay kit (Agilent Technology, Santa Clara,
CA, USA). The pre-amplified DNA library was further diluted to 6 pM to perform emulsion PCR
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with Ion Sphere™ Particles (ISPs) using the Ion OneTouch System II (Thermo Fisher Scientific Korea
Inc., Seoul, Korea) followed by enrichment of template-positive ISPs with Dynabeads™ MyOne™
streptavidin C1 beads (Thermo Fisher Scientific, Waltham, MA, USA). Each sample was loaded on
an Ion 316 Chip Kit v2 bar-coded chip. Sequencing was performed on the Ion Torrent PGM for 1200
flows with an Ion PGM™ Hi Q Sequencing Kit (Thermo Fisher Scientific Korea Inc., Seoul, Korea).
The Torrent Suite™ and Ion Torrent PGM-specific pipeline software was employed to generate sequence
reads, trim adapter sequences, filter, and remove low-quality signal-profile reads. Quality filtering of
generated sequences and taxonomic classification were performed using QIIME software based on the
Greengenes database [44].
4.5. TaqMan Probe and Primer Design
Five bacterial species from the three dominant phyla in the human gut (Bacteroidetes, Firmicutes,
and Proteobacteria) were used for probe design (Table 9.). Complete 16S rRNA gene sequences from
15 strains representing the three phyla were downloaded from the National Center for Biotechnology
Information (NCBI) GeneBank database. Multiple sequence alignments of the 16S rRNA gene
sequences from the 15 strains were performed using CLC Main Workbench 8.1 software (Qiagen,
Hilden, Germany). Following alignment, a primer pair targeting the 16S rRNA of Eubacteria was
designed from a conserved region of all strains, and phylum-specific TaqMan probes were selected
from the consensus sequence of each phylum. All probes were designed to be within the binding site
of the eubacteria primer pair. A universal probe for eubacteria that targets the opposite strand of the
conserved region of the three phyla was used [22]. The specificity of the primer pair and TaqMan
probes were confirmed by in silico analysis using the SILVA database [37].
Table 9. Bacterial strains of different phyla used to design phylum-specific primer-probe sets.
Target Phylum Strain Accession Number
Bacteroidetes Bacteroides fragilis ATCC 25285 KP326374
Bacteroides thetaiotaomicron JCM 5827 NR_112944
Bacteroides coprophilus CB42 (T) AB260026
Prevotella copri DSM 18205 NR_040877
Prevotella brevis GA33 NR_041954
Firmicutes Ruminococcus gnavus ATCC 29149 NR_036800
Clostridium difficle ATCC 9689 (T) NR_112172
Faecalibacterium prausnitzii ATCC 27768 (T) AJ413954
Enterococcus faecium IMAU20967 MK369883
Roseburia hominis A2-183 (T) AJ270482
Proteobacteria Shigella sonnei CECT 4887 FR870445
Enterobacter cloacae ATCC 13047 (T) NR_102794
Enterobacter aerogenes ATCC 13048 (T) KF516237
Escherichia coli JCM 1649 AB242910
Pseudomonas aeruginosa UTIRB3 MH910498
4.6. Conventional PCR Assay
Before conducting the multiplex TaqMan qPCR (mTqPCR) assay, conventional PCR assays were
performed to determine the specificity of the designed primer/probe sets using a Mastercycler Nexus
PCR machine (Eppendorf, Hamburg, Germany). The primer pairs and TaqMan probes were purchased
from Integrated DNA Technologies (IDT, Coralvile, IA, USA). Conventional PCR reactions were 50 µL
and were composed of 1 µL of each forward primer (Eub268), 1 µL of universal primer (1492R), 25 µL
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of EmeraldAmp Max PCR Master Mix (Takara, Japan), and 1 µL of genomic DNA from one of the
three strains from the three phyla. Sterilized ultra-pure water was used to make up a total reaction
volume of 50 µL. Genomic DNA from the three strains (B. fragilis GUT-04, C. butyricum TO-A, and
S. sonnei KCCM 41282) was added separately. After confirming the specificity of each primer and
probe set for their respective phyla, the sets were further evaluated by introducing a mock community
(i.e., a mixture of the template DNA from the above-mentioned strains in equal proportions) into the
MTq-PCR reaction. All PCR assays were performed with the following thermocycling program: 95 ◦C
for 5 min; 35 cycles of 95 ◦C for 30 s, 60 ◦C for 30 s, and 72 ◦C for 30 s; and a final extension at 72 ◦C for
5 min. PCR mixtures using universal primers (both forward and reverse) served as positive controls.
PCR mixtures without a template DNA served as negative controls.
4.7. Multiplex TaqMan qPCR
In order to quantify the relative proportions of the three phyla (Bacteroidetes, Firmicutes, and
Proteobacteria) in fecal samples from UC patients and healthy subjects, a multiplex, real-time TaqMan
qPCR was carried out using a CFX96 (Bio-Rad, Hercules, USA). All qPCR reactions for both healthy
and UC samples were performed in duplicate, and the average cycle threshold (Ct) values were
calculated. Each qPCR reaction was 20 µL and was comprised of 10 µL of 2 X qPCR master mix
(MGmed, Seoul, Korea), 1 µL of each primer, 0.5 µL of each probe, 1 µL of sample DNA, and sterilized
ultra-pure water to make up a total reaction volume of 20 µL. Based on the conventional results,
simultaneous quantification of the three phyla was performed with three TaqMan probes labeled
with three distinct fluorophores. Bacteriodetes, Firmicutes, Proteobacteria, and Eubacteria probes
were labeled with 6-FAM/BHQ1, HEX/BHQ1, Cy5/BHQ2, and TEX615/BHQ2, respectively (Figure 6).
All qPCR reactions were performed using the following thermocycling program: initial denaturation at
95 ◦C for 5 min and 40 cycles of 30 s at 95 ◦C, 30 s at 60 ◦C, and 30 s at 72 ◦C. The relative proportions of
Bacteroidetes, Firmicutes, and Proteobacteria were calculated as follows. The Ct values of each phylum
were normalized by subtracting their respective Ct values from 40, and the resulting Ct values were
summed to give a total Ct value. The relative abundance of each phylum was calculated by dividing
their respective normalized Ct value with the total Ct value, and was expressed as a percentage by
multiplying the resulting ratio by 100.
Figure 6. Schematic view of the multiplex TaqMan qPCR for simultaneous detection of the three
dominant phyla in gut microflora (Bacteroidetes, Firmicutes, and Proteobacteria) in one PCR reaction.
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4.8. Statistical Analysis
A comparison of the relative abundances from NGS and TaqMan qPCR assays was conducted
using Calypso version 8.84 [45]. The statistical similarity between NGS and TaqMan qPCR was
performed using the analysis of similarities (ANOSIM) test. A dissimilarity analysis was performed
using permutational manova (PERMANOVA, Adonis function) [46]. The similarity and dissimilarity
analyses were computed based on Bray–Curtis distance.
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